Novo Nordisk A S
NVO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000353278
No open-market purchases or sales by Novo Nordisk A S insiders were filed in the last 90 days; 1,355 institutions reported holding it in 13F filings for Q2 2026, worth $15.7B in total; superinvestors Markel Group and Maverick Capital hold it.
Other share classesNONOF
13F holders, Q1 2023
Institutional positions in Novo Nordisk A S as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,148
- +122 vs. Q4 2022
- Shares held
- 142.8M
- −318.7K (−0.2%) vs. Q4 2022
- Total value
- $22.1B
- +$2.76B (+14.2%) vs. Q4 2022
- New holders
- 175
- 326 more added
- Sold out
- 53
- 429 more reduced
24 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,355 | $15.7B |
| Q1 2026 | 1,278 | $12.0B |
| Q4 2025 | 1,421 | $16.0B |
| Q3 2025 | 1,401 | $16.7B |
| Q2 2025 | 1,486 | $21.3B |
| Q1 2025 | 1,535 | $22.5B |
| Q4 2024 | 1,670 | $29.1B |
| Q3 2024 | 1,787 | $39.7B |
| Q2 2024 | 1,867 | $47.9B |
| Q1 2024 | 1,746 | $41.8B |
| Q4 2023 | 1,512 | $32.2B |
| Q3 2023 | 1,308 | $27.4B |
| Q2 2023 | 1,198 | $23.2B |
| Q1 2023 | 1,148 | $22.1B |
| Q4 2022 | 1,050 | $19.4B |
| Q3 2022 | 908 | $13.8B |
| Q2 2022 | 934 | $16.4B |
| Q1 2022 | 902 | $15.2B |
| Q4 2021 | 887 | $14.7B |
| Q3 2021 | 806 | $12.7B |
| Q2 2021 | 737 | $11.0B |
| Q1 2021 | 708 | $8.87B |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Novo Nordisk A S; share changes are against Q4 2022.